Bio/Pharma News

The multi-product biopharmaceutical manufacturing facility is scheduled to start up in 2017.

Biomanufacturing capacity expansion uses modular cleanroom design and single-use technologies.

The agency emphasizes the need for robust scientific assessment and more information on safety and efficacy profiles of Ebola therapies in development.

Venair Biotech specializes in single-use products for the biotech and pharmaceutical sectors.

Under an NIH contract, Paragon Bioservices will design a manufacturing process for recombinant human rhE-selectin protein.

The acquisition will enhance Merck's "superbug" medication portfolio.

Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.

The US Federal Trade Commission will require Novartis AG to divest its nicotine replacement therapy patch business to continue the joint venture with GlaxoSmithKline.

Dalton Pharma Services announced it was awarded funding from ISTPCanada for its project to develop vaccines for respiratory syncytial virus and parainfluenza type 3.

The company's lead candidate, MGB-BP-3, has shown promising results against a broad range of multi-resistant Gram-positive strains.

The Singapore API facility will be operational by 2016.

The more than $200 million project will increase production capacity at the facility to support AstraZeneca':s maturing pipeline.

An index from the Access to Medicine Foundation ranks GSK as most effective in making products accessible.

Ulf Wiinberg has resigned as Lundbeck's CEO over unapproved acceptance of shares in a biotech company.

GSK and Novartis announced a meeting on Dec. 18, 2014 to discuss the $20 billion asset swap between the two companies.

GSK Australia's Boronia site will install next-generation blow-fill-seal machinery for aseptic filling.

Shire will establish its US operational headquarters in Massachusetts and relocate staff from Pennsylvania.

Pfizer will pay $850 million upfront and as much as $2 billion later in a deal to jointly develop one of Merck?s cancer drugs.

The transaction provides Allergan stockholders with immediate value and enhanced commercial opportunities, according to a company statement.

The agency cites deviations from CGMPs for the manufacture of APIs at the company?s Gujarat, India plant.

The Alios Biopharma acquisition strengthens J&J's infectious disease pipeline.

ValiRx entered into a collaboration agreement with the Deutsches Krebsforschungzentrum cancer research center.

FDA gives orphan drug designation to Merrimack Pharmaceuticals MM-141 for the treatment of pancreatic cancer.

Construction has started on Novo Nordisk's laboratories for diabetes research in Denmark.

MedImmune enters into an agreement to acquire the image analysis and data mining company.

Bristol-Myers Squibb entered into an agreement with Galecto Biotech AB to gain exclusive rights to TD139, a novel inhaled inhibitor of galectin-3 for the treatment of idiopathic pulmonary fibrosis.

Amgen is suing Sandoz over Sandoz's biosimilar application for filgrastim.

Sigma-Aldrich's custom manufacturing services business unit, SAFC, has launched a new protein quality supplement for biological drug production, including biosimilars.

The new Argos biomanufacturing facility in North Carolina will include automated production using the company's Arcelis technology.

The board of directors at Sanofi unanimously agree to remove Sanofi's CEO.